Last reviewed 2026-05-31 · How we verify

Ongentys 50mg

SK Chemicals Co., Ltd. · FDA-approved active Small molecule ✓ Verified May 2026 Quality 0/100

Ongentys 50mg is a Small molecule drug developed by SK Chemicals Co., Ltd.. It is currently FDA-approved.

Ongentys 50mg is a small molecule inhibitor of the enzyme catechol O-methyltransferase. It is used to treat Parkinson Disease, specifically the wearing-off phenomenon, as an add-on therapy to existing treatments.

At a glance

Generic name	Ongentys 50mg
Sponsor	SK Chemicals Co., Ltd.
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ongentys 50mg CI brief — competitive landscape report
Ongentys 50mg updates RSS · CI watch RSS
SK Chemicals Co., Ltd. portfolio CI

Frequently asked questions about Ongentys 50mg

What is Ongentys 50mg?

Ongentys 50mg is a Small molecule drug developed by SK Chemicals Co., Ltd..

Who makes Ongentys 50mg?

Ongentys 50mg is developed and marketed by SK Chemicals Co., Ltd. (see full SK Chemicals Co., Ltd. pipeline at /company/sk-chemicals-co-ltd).

What development phase is Ongentys 50mg in?

Ongentys 50mg is FDA-approved (marketed).

Manufacturer: SK Chemicals Co., Ltd. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing